The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study.
F. R. Khuri
No relevant relationships to disclose
T. K. Owonikoko
No relevant relationships to disclose
J. Subramanian
No relevant relationships to disclose
G. Sica
No relevant relationships to disclose
M. Behera
No relevant relationships to disclose
N. F. Saba
No relevant relationships to disclose
Z. Chen
No relevant relationships to disclose
M. Tighiouart
No relevant relationships to disclose
D. M. Shin
No relevant relationships to disclose
S. Sun
No relevant relationships to disclose
R. Fu
No relevant relationships to disclose
A. Gal
No relevant relationships to disclose
R. Govindan
No relevant relationships to disclose
S. S. Ramalingam
No relevant relationships to disclose